|Application ||WB, IHC-P, E|
|Dilution||ELISA (1:64000), IHC-P (5 µg/ml), WB (1-3 µg/ml)|
|Other Names||Melanoma-derived growth regulatory protein, Melanoma inhibitory activity protein, MIA|
|Target/Specificity||Human MIA. The immunizing peptide represents the N terminus of the mature protein. Reported variants represent identical protein: NP_006524.1, NP_001189482.1,|
|Reconstitution & Storage||Store at -20°C. Minimize freezing and thawing.|
|Precautions||MIA Antibody (Internal) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Elicits growth inhibition on melanoma cells in vitro as well as some other neuroectodermal tumors, including gliomas.|
|Tissue Location||All malignant melanoma cell lines tested and infrequently in glioma cell lines|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Elicits growth inhibition on melanoma cells in vitro as well as some other neuroectodermal tumors, including gliomas.
Blesch A.,et al.Cancer Res. 54:5695-5701(1994).
Bosserhoff A.-K.,et al.J. Biol. Chem. 271:490-495(1996).
Hau P.,et al.J. Invest. Dermatol. 119:562-569(2002).
Kalnine N.,et al.Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
Ebert L.,et al.Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.